Income Statement
APOGEE THERAPEUTICS, INC.
APGE
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
- | - | - |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
- | - | - |
|
Operating Expenses
|
285.60 | 216.87 | 93.00 |
|
Research & Development
|
214.71 | 167.87 | 68.42 |
|
Selling, General & Administrative
|
70.88 | 49.01 | 24.58 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-285.60 | -216.87 | -93.00 |
|
Non-Operating Income
|
-30.03 | -34.74 | - |
|
Interest Income
|
30.03 | 34.74 | 9.02 |
|
Interest Expense
|
- | - | - |
|
Other Non-Op Income / Expense
|
30.03 | 34.74 | 9.02 |
|
Income Before Tax
|
-255.57 | -182.13 | - |
|
Income Tax Expense
|
0.28 | 0.02 | - |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-255.84 | -182.15 | -83.99 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-285.60 | -216.87 | -93.00 |
|
Earnings Per Share (Basic)
|
-4.22 | -3.30 | -3.36 |
|
Diluted EPS
|
-4.22 | -3.30 | -3.36 |
|
Weighted Average Shares
|
60.69 | 55.19 | 25.01 |
|
Diluted Weighted Avg Shares
|
60.69 | 55.19 | 25.01 |
|
Comprehensive Income
|
-255.68 | -181.56 | -83.66 |